The Columbia Structural Heart & Valve Center physicians are pioneers in investigating treatment solutions for valve disease. We served as the lead investigational site for the PARTNER and PARTNER II clinical trials under the leadership of National PIs Martin Leon, MD and Craig Smith, MD. As a result of our involvement, the Columbia Structural Heart & Valve Center has now performed close to 2,500 TAVRs. Today, we are involved in the PARTNER 3 trial, which is evaluating TAVR for an expanded patient population. Currently, the Center is involved in three studies examining additional therapy options for the mitral valve and for the tricuspid valve.
CUMC is also is a leader in academic throughput and in 2012 published eight papers alone on the PARTNER Trial in some of the most prestigious medical journals in the world including two in the New England Journal of Medicine:
- Two-year outcomes after transcatheter or surgical aortic-valve replacement
- TAVR for inoperable severe AS.
In fact, CUMC serves as the PARTNER Publications Office in collaboration with our partners, establishing a new model for clinical trial publications. Additionally, under the leadership of Martin B. Leon, MD, CUMC founded the Valve Academic Research Consortium (VARC) which helped to standardized endpoint definitions for TAVR.
Finally, our Center serves as one of just a few training sites in the United States on TAVR. In fact, CUMC has trained close to 50 percent of the heart teams in the U.S. who now perform TAVR in their own centers.